26 October 2022

Scancell Holdings plc

("Scancell" or the "Company")

Directorate Changes

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies, today announces that John Chiplin intends to resign his role as Executive Chairman and Non-Executive Director of the Company for personal reasons but is staying on for an interim period until a new Chair is appointed.

The Board has initiated a formal search for a new Chair and a further announcement regarding details and timings will be made in due course.

The Board also announces that Richard Goodfellow intends to retire as Non-Executive Director of the Company and will not seek re-election at the upcoming AGM.

The Board also confirms that they have appointed Susan Clement Davies, an independent Non-Executive Director and Chair of the Audit Committee, as Deputy Chair.

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "The Board wishes to express its sincere thanks to John for his excellent stewardship, support and enthusiasm throughout his tenure as Executive Chairman. We are pleased that he will be with us for a while longer.

"The Board also wishes to express its gratitude to Richard. As Scancell's co-founder and until 2017 its CEO Richard has been instrumental in Scancell's evolution. His unfailing support and vision has been an inspiration to everyone involved at Scancell. We wish Richard a long and happy retirement."

Dr John Chiplin, Executive Chairman, Scancell, commented: "It has been a privilege and pleasure to have chaired the Scancell Board over the last six years. As I plan to hand over the reins to a successor, I will be leaving the Company well financed, with an exciting product pipeline, a strong management team and a high-quality shareholder base. I certainly will continue to remain a supportive shareholder.''

Dr Richard Goodfellow, Non-Executive Director, Scancell, commented: "Scancell was founded over 20 years ago from Lindy's innovative and visionary research and it has been a privilege to have been involved in the evolution of the Company from a few highly original ideas to an established biotechnology company with three products in clinical trials and its first commercially significant deal. I remain hugely optimistic about the future of the Company and I am sure that the best is yet to come."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/